Scripps VIVO scripps research logo

  • Index
  • Log in
  • Home
  • People
  • Organizations
  • Research
  • Events
Search form

Prior aspirin use predicts worse outcomes in patients with non-st-elevation acute coronary syndromes

Academic Article
uri icon
  • Overview
  • Identity
  • Additional Document Info
  • View All
scroll to property group menus

Overview

authors

  • Alexander, J. H.
  • Harrington, R. A.
  • Tuttle, R. H.
  • Berdan, L. G.
  • Lincoff, A. M.
  • Deckers, J. W.
  • Simoons, M. L.
  • Guerci, A.
  • Hochman, J. S.
  • Wilcox, R. G.
  • Kitt, M. M.
  • Eisenberg, P. R.
  • Califf, R. M.
  • Topol, Eric
  • Karsh, K.
  • Ruzyllo, W.
  • Stepinska, J.
  • Widimsky, P.
  • Boland, J. B.
  • Armstrong, P. W.
  • Investigators, Pursuit

publication date

  • 1999

journal

  • American Journal of Cardiology  Journal

abstract

  • Aspirin is beneficial in the prevention and treatment of cardiovascular events, but patients who have events while taking aspirin may have worse outcomes than those not on aspirin. We investigated the association between prior aspirin use and clinical outcomes in 9,461 patients with non-ST-elevation acute coronary syndromes enrolled in the Platelet IIb/IIIa in Unstable angina: Receptor Suppression Using Integrilin Therapy (PURSUIT) trial, before and after adjustment for baseline factors. We also examined whether eptifibatide has a differential treatment effect in prior aspirin users. Prior aspirin users were less likely to have an enrollment myocardial infarction (MI) (vs unstable angina) (43.9% vs 48.8%, p = 0.001) but more likely to have death or MI at 30 days (16.1% vs 13.0%, p = 0.001) and at 6 months (19.9% vs 15.9%, p = 0.001). After adjustment, prior aspirin users remained less likely to have an enrollment MI (odds ratio 0.88, 95% confidence interval 0.79 to 0.97) and more likely to have death or MI at 30 days (odds ratio 1.16, 95% confidence interval 1.00 to 1.33) but not at 6 months (odds ratio 1.14, 95% confidence interval 0.98 to 1.33). In a multivariable model, eptifibatide did not have a different treatment effect in prior aspirin users compared with nonusers (p = 0.534). Prior aspirin users had fewer enrollment MIs but worse long-term outcomes than nonusers. We found no evidence for a different treatment effect of eptifibatide in prior aspirin users.

subject areas

  • Acute Disease
  • Aged
  • Angina, Unstable
  • Aspirin
  • Electrocardiography
  • Female
  • Follow-Up Studies
  • Humans
  • Male
  • Middle Aged
  • Odds Ratio
  • Peptides
  • Platelet Aggregation Inhibitors
  • Prognosis
  • Safety
  • Survival Rate
  • Syndrome
scroll to property group menus

Identity

International Standard Serial Number (ISSN)

  • 0002-9149

Digital Object Identifier (DOI)

  • 10.1016/s0002-9149(99)00049-1

PubMed ID

  • 10215274
scroll to property group menus

Additional Document Info

start page

  • 1147

end page

  • 1151

volume

  • 83

issue

  • 8

©2019 The Scripps Research Institute | Terms of Use | Powered by VIVO

  • About
  • Contact Us
  • Support